THYROCAREBSEThyrocare Technologies LtdMinimalNeutral
Announced Sat, 9 May · 12:26 IST

Please find attached herewith Newspaper Publications of Audited Financial Results for the quarter and financial year ended on March 31, 2026

THYROCARE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-2.9%1-day move
₹486.00
prior close
₹488.90
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-1.0-0.1+0.3-0.8-2.9-1.6-3.3-5.1-6.7-2.3+7.4+7.6+4.5
Up moveDown movePending
AI summary

Thyrocare Technologies Ltd published its audited financial results for Q4 and full year ended March 31, 2026, in Navshakti (Marathi) and Business Standard (English) newspapers, as required under SEBI Listing Regulations. Total income from operations grew to Rs. 846.03 Cr for FY 2025-26, up ~20.5% from Rs. 702.18 Cr in FY 2024-25. Net profit after tax more than doubled to Rs. 212.88 Cr from Rs. 145.44 Cr year-on-year. Q4 FY 2026 standalone revenue stood at Rs. 228.26 Cr with net profit of Rs. 64.43 Cr. EBITDA for the full year was Rs. 217.65 Cr vs Rs. 146.88 Cr in the prior year. EPS for FY 2025-26 was Rs. 10.24 per share (basic and diluted), compared to Rs. 5.69 in FY 2024-25. The board approved the results at its meeting on May 8, 2026. Statutory auditors issued an unmodified audit opinion.

Likely market impact

Strong double-digit revenue growth and near-doubling of net profit signal improving operational performance. The significant EPS growth from Rs. 5.69 to Rs. 10.24 is a positive indicator for shareholders, reflecting both topline strength and improved profitability margins year-on-year.